Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Key Points
Key points are not available for this paper at this time.
Abstract
Comparison of the structure of 9MW2821 and enfortumab vedotin.
Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse